Groupe Hospitalier Diaconesses Croix Saint Simon

The oncology department at Groupe Hospitalier Diaconesses Croix Saint Simon is advancing cancer care through trials on breast neoplasms, prostate adenocarcinoma, and colon carcinoma, evaluating targeted agents, neo‑adjuvant regimens, and circulating tumor DNA‑guided strategies.

• Targeted endocrine therapy for hormone‑responsive breast cancer
• Neo‑adjuvant FOLFOX chemotherapy in resectable colon cancer
• ctDNA‑directed treatment selection after surgery
• Comparative study of ADT plus darolutamide versus ADT alone
• Evaluation of novel oral SERD imlunestrant in early breast cancer

Multidisciplinary collaboration across medical oncology, surgery, and radiology drives innovative approaches to improve survival and quality of life.

A phase III investigation at the site focuses on patients with severe community‑acquired pneumonia, testing the immunomodulator trimodulin to reduce 28‑day all‑cause mortality.

• Immunomodulatory therapy for severe pneumonia
• Hospitalized adult patient outcomes
• Mortality and safety endpoints
• Biomarker and inflammatory response analysis
• Integration with standard antimicrobial care

The pulmonary unit works closely with intensive‑care specialists to bring novel treatments to critically ill patients.

Researchers are evaluating secukinumab in individuals with moderate to severe rotator cuff tendinopathy, aiming to alleviate shoulder pain and improve functional scores by week 16.

• IL‑17 inhibition for tendon inflammation
• Physical symptom relief and mobility enhancement
• Patient‑reported outcome measures
• Safety and tolerability monitoring
• Comparative analysis against placebo

Orthopedic and rheumatology teams jointly manage the trial to address unmet needs in musculoskeletal health.

The centre conducts studies on colon carcinoma, including age‑adapted neo‑adjuvant chemotherapy and ctDNA‑guided adjuvant strategies, to enhance disease‑free survival after surgery.

• Neo‑adjuvant FOLFOX in elderly patients
• ctDNA surveillance for recurrence risk
• Optimization of adjuvant chemotherapy selection
• Surgical outcome comparisons
• Long‑term follow‑up of disease‑free intervals

A collaborative effort between surgical oncology, medical oncology, and pathology supports personalized colorectal cancer care.

An infection‑focused trial investigates the safety and efficacy of rifampicin in treating C. spp. prosthetic joint infection, seeking to improve eradication rates while preserving joint function.

• Antibiotic safety profiling in prosthetic joint infections
• Efficacy assessment of rifampicin regimens
• Monitoring of microbial resistance patterns
• Functional outcome evaluation post‑treatment
• Integration with surgical debridement protocols

Infectious disease specialists partner with orthopedic surgeons to refine management of complex prosthetic infections.